Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27

  • Authors:
    • Jing Li
    • Xiaomei Zhang
    • Jiaying Shen
    • Jun Guo
    • Xiaolin Wang
    • Jiaqiang Liu
  • View Affiliations

  • Published online on: July 3, 2019     https://doi.org/10.3892/mmr.2019.10467
  • Pages: 2410-2418
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the effect of bortezomib on heat shock protein 27 (HSP27) in multiple myeloma (MM) and provide a potential new target for clinical treatment. Peripheral blood was collected from 50 normal subjects and 50 patients with newly diagnosed MM and the expression of HSP27 was detected by ELISA. The changes of HSP27 after conventional vincristine, doxorubicin and dexamethasone (VAD) chemotherapy, and bortezomib plus VAD were compared. The effect of bortezomib on U266 cell proliferation and apoptosis was detected using a Cell Counting Kit‑8 assay and Annexin V‑FITC/propidium iodide double staining with flow cytometry. The content of HSP27 following bortezomib treatment was determined by ELISA. Western blot analysis and reverse transcription‑quantitative PCR were used to detect the mRNA and protein expression of HSP27, Bax and Bcl‑2. HSP27 expression was increased in patients with MM compared with healthy control subjects, and the expression was increased as the cancer progressed (P<0.05). Compared with the VAD chemotherapy group, the bortezomib plus VAD chemotherapy regimen significantly inhibited the expression of HSP27 (P<0.05), and the content of HSP27 was decreased in patients in which treatment was effective compared to those patients that exhibited disease progression (P<0.05). The efficacy of the treatment regimes was not associated with age or gender. Compared with the control group, bortezomib or OGX‑427 (HSP27 inhibitor) treatment inhibited U266 cell proliferation, promoted U266 cell apoptosis (P<0.05) and significantly decreased HSP27 expression (P<0.05). Furthermore, the expression of HSP27 and Bcl‑2 was significantly decreased, while the expression of Bax was increased by bortezomib and OGX‑427 (P<0.05). There was no significant difference between the bortezomib and OGX‑427 group in the in vitro analysis. HSP27 was positively correlated with Bcl‑2 expression and negatively correlated with Bax expression in U266 cells. In conclusion, bortezomib promotes the apoptosis of MM cells, potentially by downregulating the expression of HSP27, providing a potential novel target for the clinical treatment of multiple myeloma.

References

1 

Palumbo A and Anderson K: Multiple myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Zhang L, Fok JH and Davies FE: Heat shock proteins in multiple myeloma. Oncotarget. 5:1132–1148. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ, et al: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388:1545–1602. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Michels TC and Petersen KE: Multiple myeloma: Diagnosis and treatment. Am Fam Physician. 95:373–383. 2017.PubMed/NCBI

5 

Mahindra A, Hideshima T and Anderson KC: Multiple myeloma: Biology of the disease. Blood Rev. 24 (Suppl 1):S5–S11. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Khan SA and Cohen AD: Experimental approaches in the treatment of multiple myeloma. Ther Adv Hematol. 2:213–230. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Costa LJ, Gonsalves WI and Kumar S: Early mortality in multiple myeloma: Risk factors and impact on population outcomes. Blood. 124:13202014.PubMed/NCBI

8 

Peña C, Rojas C, Rojas H, Soto P, Cardemil D, Aranda S, Contreras C, La Roca G, Russo M, Pérez C, et al: Survival of 1,103 Chilean patients with multiple myeloma receiving different therapeutic protocols from 2000 to 2016. Rev Med Chil. 146:869–875. 2018.(In Spanish). View Article : Google Scholar : PubMed/NCBI

9 

Landgren O: Shall we treat smoldering multiple myeloma in the near future? Hematology Am Soc Hematol Educ Program. 2017:194–204. 2017. View Article : Google Scholar : PubMed/NCBI

10 

Briqle K and Roqers B: Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 33:225–236. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Abdalla AO, Kokhaei P, Hansson L, Mellstedt H and Osterborg A: Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol. 19:1172–1179. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Khandia R, Munjal AK, Iqbal HMN and Dhama K: Heat shock proteins: Therapeutic perspectives in inflammatory disorders. Recent Pat Inflamm Allergy Drug Discov. 10:94–104. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Calderwood SK and Gong J: Heat shock proteins promote cancer: It's a protection racket. Trends Biochem Sci. 41:311–323. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Campanella C, Rappa F, Sciumè C, Marino Gammazza A, Barone R, Bucchieri F, David S, Curcurù G, Caruso Bavisotto C, Pitruzzella A, et al: Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery. Cancer. 121:3230–3229. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS and Anderson KC: Tanespimycin monotherapy in relapsed multiple myeloma: Results of a phase 1 dose-escalation study. Br J Haematol. 150:438–445. 2010.PubMed/NCBI

16 

Richardson PG, Chanan-Khan AA, onial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M and Anderson KC: Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: Results of a phase 1/2 study. Br J Haematol. 153:729–740. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Stühmer T, Zöllinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kortüm M, Unzicker C, Jensen MR, Quadt C, et al: Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia. 22:1604–1612. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Yu Z, Zhi J, Peng X, Zhong X and Xu A: Clinical significance of HSP27 expression in colorectal cancer. Mol Med Rep. 3:953–958. 2010.PubMed/NCBI

19 

Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y and Foster CS: Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 60:7099–7105. 2000.PubMed/NCBI

20 

Conroy SE, Sasieni PD, Amin V, Wang DY, Smith P, Fentiman IS and Latchman DS: Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br J Cancer. 77:1875–1879. 1998. View Article : Google Scholar : PubMed/NCBI

21 

Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, et al: Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 102:3379–3386. 2003. View Article : Google Scholar : PubMed/NCBI

22 

Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH and Van der Zee AG: Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: Relation in response to chemotherapy and prognosis. Int J Cancer. 84:234–238. 1999. View Article : Google Scholar : PubMed/NCBI

23 

Richardson PG, Hideshima T and Anderson KC: Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 10:361–369. 2003. View Article : Google Scholar : PubMed/NCBI

24 

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al: International Mye-loma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI

25 

Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI

26 

Durie BG and Salmon SE: A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI

27 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

28 

Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC: Multiple myeloma. Lancet. 374:324–339. 2009. View Article : Google Scholar : PubMed/NCBI

29 

Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S and Shiotsu Y: New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res. 16:2792–2802. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Eugênio AIP, Fook-Alves VL, de Oliveira MB, Fernando RC, Zanatta DB, Strauss BE, Silva MRR, Porcionatto MA and Colleoni GWB: Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma. Oncotarget. 8:114698–114709. 2017. View Article : Google Scholar : PubMed/NCBI

31 

Boccadoro M, Morgan G and Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5:182005. View Article : Google Scholar : PubMed/NCBI

32 

Adams J: Proteasome inhibition in cancer: Development of PS-341. Semin Oncol. 28:613–619. 2001. View Article : Google Scholar : PubMed/NCBI

33 

Ciocca DR and Vargas-Roig LM: Hsp27 as a prognostic and predictive factor in cancer. Prog Mol Subcell Bill. 28:205–218. 2002. View Article : Google Scholar

34 

Wei L, Liu TT, Wang HH, Hong HM, Yu AL, Feng HP and Chang WW: Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB. Breast Cancer Res. 13:R1012011. View Article : Google Scholar : PubMed/NCBI

35 

Gonzalez-Mejia ME, Voss OH, Murnan EJ and Doseff AI: Apigenin-induced apoptosis of leukemia cells is mediated by a bimodal and differentially regulated residue-specific phosphorylation of heat-shock protein-27. Cell Death Dis. 1:e642010. View Article : Google Scholar : PubMed/NCBI

36 

Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M and Garrido C: Heat shock proteins: Essential proteins for apoptosis regulation. J Cell Mol Med. 12:743–761. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 20 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, J., Zhang, X., Shen, J., Guo, J., Wang, X., & Liu, J. (2019). Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27. Molecular Medicine Reports, 20, 2410-2418. https://doi.org/10.3892/mmr.2019.10467
MLA
Li, J., Zhang, X., Shen, J., Guo, J., Wang, X., Liu, J."Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27". Molecular Medicine Reports 20.3 (2019): 2410-2418.
Chicago
Li, J., Zhang, X., Shen, J., Guo, J., Wang, X., Liu, J."Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27". Molecular Medicine Reports 20, no. 3 (2019): 2410-2418. https://doi.org/10.3892/mmr.2019.10467